[Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].

摘要: OBJECTIVE To compare the susceptibility of rifampicin (RFP) and rifabutin (RBT) against multi-drug resistant Mycobacterium tuberculosis (MDR-TB). METHOD A total 44 confirmed MDR-TB strains collected by Ryoken consortium 97 susceptible M. were tested for to RBT, following CLSI M24-A laboratory standard. The core 81bp region rpoB gene was sequenced strains, mutations defined. RESULTS Among tested, 12 RBT. genetic alterations identified in 43 strains. RBT had mainly at codons 506-508, 511, 512, 516. mutation 526 531 closely related resistance with two exceptions. overall cross-resistance between RFP 72.7%. DISCUSSION will be a candidate drug treatment MDR-TB. In this study, approximately 27% Japan However, testing is not easy general microbiology considering preparation medium facilities. It also difficult transfer one place another legally. are useful predict its susceptibility.